Background: Because it is insufficiently clear whether BRCA-associated epithelial ovarian cancer (EOC) is more chemosensitive than sporadic EOC, we examined response to chemotherapy, progression-free survival (PFS) and overall survival (OS) in BRCA1-and BRCA2-associated versus sporadic EOC patients.
The few studies published so far found that BRCA-associated EOC patients have a longer survival compared with sporadic EOC patients [3, [12] [13] [14] [15] [16] [17] . It has been suggested that this longer survival is caused by a better response to (platinum-based) chemotherapy. In the study of Chetrit et al. [12] , it was indeed observed that the longer survival was mainly seen in the patient group treated with first-line chemotherapy.
In vitro testing showed that BRCA1-and BRCA2-deficient cells are associated with a higher proliferation rate, chromosomal instability and a deficiency to repair doublestrand DNA breaks by homologous recombination [18] [19] [20] . The latter biological mechanism may be responsible for an increased chemosensitivity, which might result in a longer PFS and OS, compared with sporadic patients. This mechanism may be especially valid for platinum (analogues) since this type of drugs act at the DNA level by formation of cross links, leading to double-strand DNA breaks and replication arrest [21, 22] .
Data about response to platinum-based therapy in BRCA1/2 EOC patients are scarce. Most of the studies reporting a longer survival in BRCA1/2-associated EOC patients lack detailed data about chemotherapy [12, 14, 15, 23, 24] . So far, only one small study by Tan et al. [3] (22 BRCA-positive patients) has investigated the response to platinum-containing chemotherapy in BRCA1/2-associated EOC patients. They found that BRCA mutation carriers had a better response to platinum-based chemotherapy.
Whether the outcomes of BRCA1-and BRCA2-associated EOC differ is insufficiently known. From the available literature, it appears that the survival of BRCA2-associated EOC may be more favourable compared with BRCA1-linked EOC [12, 14, 15, 23, 25] .
In this analysis, we evaluated the response to, as well as the progression-free survival (PFS) and overall survival (OS) after primary therapy, including first-line chemotherapy in 99 BRCA1-associated and 13 BRCA2-associated EOC patients, respectively, in comparison with 222 matched sporadic EOC patients.
patients and methods
From the database of the Rotterdam Family Cancer Clinic of the Erasmus University Medical Center (MC)-Daniel den Hoed Cancer Center, we identified all EOC patients, belonging to a proven BRCA1 or BRCA2 mutation family, diagnosed between 1 January 1980 and 1 January 2009. Follow-up information was collected until 1 June 2009. The BRCA1/2 mutation carriers were matched (1 : 2) with sporadic EOC patients for age at (65 years) and period of diagnosis (65 years). Sporadic patients were selected from the cancer registry of the institution or the Comprehensive Cancer Center, Rotterdam. Sporadic EOC patients with a family history of breast and/or ovarian cancer, defined as two relatives (first or second degree) with breast cancer, one relative (first or second degree) with breast cancer diagnosed before the age of 55 years and/or one relative (first or second degree) with ovarian cancer, irrespective of age, were excluded. Inclusion criteria were data availability about patient and tumour characteristics, first-line chemotherapy administered as part of primary treatment and adequate follow-up data. Excluded were patients with a borderline ovarian tumour, suspicion of primary or recurrent breast cancer or another malignancy before the development of ovarian cancer. For all the BRCA-positive patients, DNA testing was carried out in the Department of Clinical Genetics at the Erasmus MC, Rotterdam. Methods of DNA testing have previously been described [22] .
We identified 113 BRCA1-and 16 BRCA2-associated EOC patients diagnosed between 1980 and 2009. Ten patients were excluded because of incomplete follow-up. In total, 105 BRCA1-and 14 BRCA2-associated patients were matched with 238 sporadic EOC patients. Twenty patients, consisting of 5 BRCA1 (5%), 1 BRCA2 (7.7%) and 14 sporadic (6.3%) patients, were not treated with chemotherapy as part of primary treatment and were excluded from further analyses. Sixteen of these patients had a FIGO (International Federation of Gynecology and Obstetrics) stage I, being the reason for not administering chemotherapy, two patients refused chemotherapy and two patients died before chemotherapy could be given. In addition, three patients not being assessable for response to chemotherapy as they only received one chemotherapy cycle were also excluded. Ultimately, 99 BRCA1-, 13 BRCA2-associated and 222 sporadic ovarian cancer patients were included in the analyses.
For all eligible patients, information concerning patient and tumour characteristics, surgical procedure and residual tumour size, type and duration of chemotherapy, response to treatment, PFS and OS was retrospectively retrieved from medical files. Missing information was assembled as much as possible by treating physicians in regional community hospitals. Response was evaluated after end of first-line chemotherapy treatment. As most patients were treated before the introduction of the RECIST criteria (2000), the World Health Organization criteria were used to evaluate response to chemotherapy [26, 27] . The response to chemotherapy could not be determined in four patients, mostly concerning patients who were treated in the early 80s. We decided not to exclude these patients because we did have information about PFS and OS. The study was approved by the Medical Ethics Committee of the Erasmus MC, Rotterdam, The Netherlands.
statistical analysis
Differences in patient and tumour characteristics between BRCA1/2-, BRCA1-and BRCA2-associated patients, respectively, and sporadic ovarian cancer patients were tested with the Pearson chi-square test or the Fisher's exact test (categorical variables) or by the Student's t-test (continuous variables).
Study end points were response to first-line chemotherapy, PFS, ovariancancer-specific survival (OCSS) and OS. The response to chemotherapy in the BRCA1, BRCA2 and sporadic ovarian cancer patient groups, respectively, was evaluated for all the chemotherapeutic regimens together and separately for the patients being treated with platinum/taxol, a platinum-based regimen (without taxol), and non-platinum-based chemotherapy. Differences in response to first-line chemotherapy were tested with the Pearson chi-square test or, in case of small numbers, with the Fisher's exact test.
Both PFS and OS were measured using the Kaplan-Meier survival method. PFS was defined as the time between the start of chemotherapy and the date of progressive disease (PD) or first recurrence. OS was defined as the time between the start of chemotherapy and the date of death or last follow-up and OCSS as the time between the date of diagnosis and the date of death due to ovarian cancer or last follow-up.
Patients were censored in the analyses for PFS, OS and OCSS by date of last visit at the clinic or end date of this study (1 June 2009 ). In the analyses for PFS and OCSS, patients were also censored by date of death due to other reasons than ovarian cancer. Differences in PFS and OS between the three patient groups were examined in a multivariate Cox proportional hazard regression model, adjusting for possible confounders including FIGO stage, tumour grade and morphology, CA 125 at diagnosis, residual tumour after debulking surgery (<1 or >1 cm), type of chemotherapy and history of and adjuvant chemotherapy for breast cancer. All analyses were carried out with SPSS (version 15.0). A two-sided P < 0.05 was considered as statistically significant. results patient and tumour characteristics Table 1 depicts the patient and tumour characteristics. Mean age at diagnosis was 52 years (range 31.4-74.0 years). As expected, significantly more BRCA1-associated (29%) and BRCA2-associated (54%) patients had a history of breast cancer in contrast with the sporadic group (4%). The median diseasefree interval between breast and ovarian cancers was 8.1 years (range 0.02-30.1 years) in the BRCA1, 3.2 years (range 1.5-9.7 years) in the BRCA2 and 9.3 years (range 0.7-17.7 years) in the sporadic group, respectively.
Regarding tumour characteristics, no significant differences in tumour grade, FIGO stage, histology and CA 125 values were observed between the hereditary groups and the sporadic group. In the three patient groups, tumours were Annals of Oncology original article predominantly poorly differentiated and of serous histology. As a result of the selection criteria, the majority of the patients had an unfavourable FIGO stage, namely stage III/IV in 78% of BRCA1, 69% of BRCA2 and 79% of the sporadic cases, respectively. However, none of the BRCA2-associated patients had a FIGO stage IV. In the majority of patients, the CA 125 level at diagnosis was >500 kU/l. More BRCA1 (64%, P = 0.006) and BRCA2 (85%, P = 0.009) patients had a tumour residue <1 cm after cytoreductive surgery compared with sporadic patients (47%).
response to chemotherapy
No significant differences were observed in the type of administered chemotherapy between the three groups ( Table 2) . BRCA1-associated patients obtained a complete response (CR)/no evidence of disease (NED) after first-line chemotherapy in 87% (N = 83) of the cases compared with 71% (N = 158) of the sporadic patients (P = 0.002). PD was observed in only 2 BRCA1 patients (2%) compared with 34 (15%) sporadic patients. In the BRCA2 group, the response to chemotherapy was also more favourable than in the sporadic group, and none of the BRCA2 patients had PD. This, however, was not statistically significant due to the low number of BRCA2 patients (N = 13).
None of the BRCA1 and BRCA2 patients treated with a platinum-based regimen had PD, in contrast with 15% of the sporadic patients (P < 0.001). Remarkably, the two BRCA1 patients, having PD after first-line chemotherapy, did receive a non-platinum-based regimen, while both sporadic patients receiving a non-platinum-based regimen obtained a CR/NED (Table 3) .
PFS and OS
PFS was significantly longer in the BRCA1 and BRCA2 group compared with the sporadic group, namely 2.1, 5.6 and 1.3 years, respectively (Table 4 ). There was a trend for a longer PFS in BRCA2 compared with BRCA1 patients (P = 0.05). While the PFS at 2 years was higher in both hereditary groups compared with the sporadic group, the 5-year PFS rate remained high in BRCA2-associated patients (54%) and relatively decreased to 28% in BRCA1-linked patients ( Figure 1A and Table 4 ). Compared with patients with sporadic EOC, the hazard ratio (HR; BRCA versus sporadic patients) by univariate analysis for the risk of progression was 0.66 [95% confidence interval (CI) 0.5-0.87] for the BRCA1 group and 0.35 (95% CI 0.17-0.76) for the BRCA2 group (Table 5) . In a multivariate analysis, after adjusting for FIGO stage and residual tumour after debulking surgery, BRCA carriership remained significantly associated with improved PFS [BRCA1: HR 0.67 (95% CI 0.50-0.89), BRCA2: HR 0.45 (95% CI 0.21-0.97); Table 5 ]. Other tested variables (see 'Patients and Methods' section) were not found to be confounders in the analysis and therefore not included in the multivariate model.
Compared with the sporadic cohort, the OS in the BRCA1-and BRCA2-associated patients was significantly longer as well ( Figure 1B and Table 4 ). The observed median OS was 5.9 years in the BRCA1, and more than 10 years in the BRCA2 group, in comparison with 2.9 years in the sporadic group. Also, both the 2-and 5-year OS rates were significantly higher in the BRCA groups, being 84% and 60% in the BRCA1 group, 92% and 85% in the BRCA2 patients, in contrast with 64% and 37% in the sporadic group. In accordance with the pattern seen for PFS, relatively more BRCA2-associated patients remain alive at 5 as well as at 10 years in comparison with BRCA1-associated patients (P = 0.06). The HR (BRCA versus sporadic groups) by univariate analysis for the risk of death was 0.56 (95% CI 0.41-0.76) for the BRCA1 and 0.29 (95% CI 0.12-0.71) for the BRCA2 group. This remained statistically significant after correction for FIGO stage and residual tumour after cytoreductive surgery (Table 5) .
Since more BRCA patients had a history of breast cancer before the EOC diagnosis, the OCSS was also of interest (Table 4) . Although significantly more BRCA patients had a history of breast cancer compared with the sporadic group before the EOC diagnosis, only two patients (2%) died of breast cancer in the BRCA1 group and two patients (1%) in the sporadic group died of breast cancer. This resulted in a significantly better OCSS in the BRCA1 (median 6.5 years, P = 0.002) and BRCA2 groups (median >10 years, P = 0.008), respectively, compared with the sporadic group (median 3.2 years). Table 2 . Type of and response to first-line chemotherapy in BRCA1/2-, BRCA1-and BRCA2-associated and sporadic ovarian cancer patients 
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To our knowledge, the current report is the first study exploring the response to first-line chemotherapy in BRCA1-and BRCA2-associated EOC patients separately compared with sporadic EOC patients. We found that BRCA1-as well as BRCA2-associated patients with EOC have a better response after first-line chemotherapy. In fact, none of the BRCAassociated patients were refractory to first-line platinum-based chemotherapy, contrary to sporadic patients. The PFS and OS were significantly longer as well in both hereditary groups, in comparison with sporadic EOC patients and a trend for a longer PFS and OS in BRCA2-compared with BRCA1-associated ovarian cancer patients was observed. The response to first-line chemotherapy was also studied by Tan et al. [3] in 22 BRCA1/2-associated compared with sporadic EOC patients. In this smaller study, a significantly higher CR rate (81.8% versus 43.2%, P = 0.004) and longer median OS (8.4 versus 2.9 years, P < 0.002) were found for the BRCA-associated patients, being in accordance with our data. Because only 22 BRCA1/2-linked patients were included, a separate evaluation of the outcome in BRCA1 and BRCA2 patients was not carried out. In our study, 92% of the BRCA2 patients obtained CR/NED and none had PD compared with 71% and 15%, respectively, in the sporadic patients.
Compared with the sporadic patients, we found a significantly longer PFS for both the BRCA1-and BRCA2-associated patients (P = 0.006 and P = 0.008, respectively). In our opinion, this is potentially a reflection of the improved chemosensitivity to platinum-based chemotherapy of the hereditary patients and this is in accordance with previously reported data. Boyd et al. [15] also reported a significantly improved PFS for BRCA mutation carriers after first-line chemotherapy. This study, however, only included AshkenazyJewish patients having one of the founder mutations in BRCA1/2, which is not representative for the Dutch population of BRCA patients. In the study of Tan et al. [3] , an improved PFS in BRCA1/2-positive patients was described as well, although not statistically significant (18 versus 12 months, P = 0.115), which is probably due to the small number of patients.
Although the improved response to chemotherapy might be an important reason for the longer PFS, other factors might also play a role. In our BRCA2 cohort, 2 patients (15%) had a mucinous carcinoma compared with 4 (4%) BRCA1 and 19 sporadic patients (9%). It is known that mucinous EOC has a better prognosis compared with serous carcinoma [28] . However, restricting our analyses to serous carcinomas only, 92% of the BRCA1 group (P = 0.003), 88% of the BRCA2 group (P = 0.84) and 72% of the sporadic group obtained a CR/NED after chemotherapy. Also, median PFS remained significantly longer in the hereditary groups, being 2.4 years (P < 0.001) in the BRCA1 and 2.9 years (P = 0.03) in the BRCA2 group versus 1.3 years in the sporadic group (data not shown). Other variables possibly playing a role in the better outcome as observed in our BRCA2 group might be: no FIGO stage IV, no residual tumour >1 cm after surgery and no BRCA2 patient with a clear cell or endometroid histology. Further research in a greater BRCA2-associated cohort is certainly warranted.
The OS in both the BRCA1 and BRCA2 cohort of our study was significantly better compared with the sporadic cohort and again most pronounced in the BRCA2 cohort. These results remained significantly better in favour of the BRCA groups if we restricted our analyses to serous carcinomas only [median OS in BRCA1: 6.5 years (P = 0.001), in BRCA2: 6.8 years Table 4 . Progression-free survival (PFS), overall survival (OS) and ovarian-cancer-specific survival (OCSS) in BRCA1-associated, BRCA2-associated and sporadic ovarian cancer patients original article Annals of Oncology (P = 0.03), and 2.8 years in the sporadic group]. This means that our data are in accordance with the results of other studies about OS for BRCA-associated EOC patients [12, 14, 15, 23, 24, 29] . The better outcome in BRCA1-and BRCA2-associated EOC patients might partly be caused by the higher percentage of patients with tumour residue <1 cm after primary surgery (Table 1) . However, in multivariate analyses after correcting for tumour residue, PFS and OS remained significantly better in both BRCA groups. In view of the data of Tan et al. [3] who observed a better response to second-and third-line chemotherapy (without surgery) as well as a prolonged therapy-free interval after each chemotherapy line in mutation carriers, our data suggest that chemotherapy contributes to the improved outcome in BRCA1-and BRCA2-associated compared with sporadic patients.
Survival or ascertainment bias can occur by preferably selecting long-living patients who were tested a long time after their EOC diagnosis. This can especially happen in patients, diagnosed with EOC before 1995 when DNA tests for a BRCA1 or BRCA2 mutation were not available yet. In order to minimise this type of bias, we also included first-degree family members of mutation carriers affected with ovarian cancer who were not tested themselves, but based on their personal history and the position in the pedigree, these patients were considered as obligate mutation carrier. In addition, we carried out a subanalysis after exclusion of 25 BRCA-associated patients who underwent genetic testing more than 1 year after the diagnosis of EOC. All the differences between BRCA1 and sporadic patients remained significant, while PFS and OS in the BRCA2 group were not significantly longer anymore, which is probably due to the low number of patients in this group. A limitation of our study is that genetic testing in the sporadic group was not carried out. Although patients with a family history of breast/ovarian cancer were excluded, this does not rule out that some of the sporadic EOC patients might be a mutation carrier. However, the differences in outcome parameters between the proven BRCA1/2 mutation carriers and sporadic patients might then even be bigger as we described.
As the prognosis of early-stage EOC is significantly better compared with advanced-stage EOC, we also carried out a subanalysis excluding patients with FIGO stage I and IIa. In these analyses, PFS and OS remained significantly better for BRCA1-and BRCA2-associated patients compared with sporadic patients. Response to chemotherapy remained statistically significantly better for BRCA1-associated patients, while the response in the BRCA2 group was better as well, but not statistically significant.
In conclusion, BRCA1 and BRCA2 mutation carriers have a better outcome after primary therapy, including chemotherapy, compared with sporadic EOC patients. It appears that BRCA1-and BRCA2-associated EOC may very well be different entities. More fundamental research and further comparison of BRCA1-and BRCA2-associated EOC is urgently needed to specifically define the most effective treatment for the separate patient groups. Confirmation of the present findings may lead to new guidelines for the counselling and treatment of BRCA1 and BRCA2 EOC patients.
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